Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential